On Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients ...

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first once-weekly treatment for the disease.

Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain hemophilia patients. The drug will be marketed under the trade name Hympavzi ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor pathway inhibitor to be allowed for ...

The Food and Drug Administration on Friday approved a new kind of medicine for hemophilia, clearing Pfizer’s Hympavzi for people with either the “A” or “B” forms of the inherited ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved HYMPAVZI™ for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...

(RTTNews) - Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor pathway inhibitor to be allowed for ...

FDA approves Pfizer’s Hympavzi for routine prophylaxis in hemophilia A and B patients, offering a once-weekly dosing via auto-injector pen. Phase 3 trial showed Hympavzi reduced bleeding rates ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors - making it the first antitissue-factor pathway inhibitor to be allowed for ...